Mga Batayang Estadistika
| CIK | 1662579 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to C4 Therapeutics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 7, 2025 |
Exhibit 99.1 C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights Cemsidomide Phase 1 Data in Multiple Myeloma Accepted as an Oral Presentation at the International Myeloma Society (IMS) Annual Meeting; As of the July 23, 2025, Data Cutoff, Phase 1 ORR Remains at 40% at the 75 µg Dose Level and at 50% at the 100 µg Dose Level Productive Type C Meeting Held W |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39567 C4 Therapeutics, Inc. |
|
| August 7, 2025 |
augustcorporatedeckfina Protein degraded. Disease targeted. Lives transformed. August 2025 Forward-looking Statements and Intellectual Property FORWARD-LOOKING STATEMENTS The following presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” |
|
| June 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 18, 2025 |
Certificate of Amendment to the Fifth Amended and Restated Certificate of Incorporation Delaware The First State Page 1 5840223 8100 Authentication: 203978031 SR# 20253108061 Date: 06-18-25 You may verify this certificate online at corp. |
|
| May 7, 2025 |
Protein degraded. Disease targeted. Lives transformed. May 2025 Forward-looking Statements and Intellectual Property FORWARD-LOOKING STATEMENTS The following presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39567 C4 Therapeutics, Inc. |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 7, 2025 |
Exhibit 99.1 C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights Updated Cemsidomide Multiple Myeloma Data Further Demonstrate Compelling Response Rates at Multiple Doses and Potential for Best-in-Class Profile; 50% ORR Observed at the Highest Dose Level of 100 µg, Including One Patient With a Minimal Residual Disease Negative Complete Response; 40% ORR Achi |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a6(e)( |
|
| April 29, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a6(e) |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39567 C4 Therapeutics |
|
| April 16, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a6(e) |
|
| April 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2025 (April 10, 2025) C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporatio |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-395 |
|
| February 27, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 27, 2025 |
Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Incorporation C4T Securities Corporation Massachusetts |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under The Securities Act of 1933 C4 Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) Delaware 47-5617627 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 490 Arsenal Way, Suite 120 Watertown, MA 02472 (Address of princip |
|
| February 27, 2025 |
Exhibit 99.1 C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin’s Lymphoma; Trials Expected to Initiate in Early 2026 CFT1946 Phase 1/2 Trial Continues to Progress Across Multiple Cohorts; Data in Melanoma and Colorectal Canc |
|
| February 27, 2025 |
ACTIVE/128326788.11 Confidential Execution Copy Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. RESEARCH COLLABORATION AND LICENSE AGREEMENT by and between C4 THERAPE |
|
| February 27, 2025 |
ACTIVE/129481757.2 C4 THERAPEUTICS, INC. STATEMENT OF COMPANY POLICY ON INSIDER TRADING AND DISCLOSURE This memorandum sets forth the policy of C4 Therapeutics, Inc. and its subsidiaries (collectively, the “Company”) regarding trading in the Company’s securities as described below and the disclosure of information concerning the Company. This Statement of Company Policy on Insider Trading and Disc |
|
| February 27, 2025 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) C4 Therapeutics, Inc. |
|
| January 14, 2025 |
Exhibit 99.1 C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology Cemsidomide Data Presented at American Society of Hematology (ASH) Annual Meeting Support Best-in-Class Profile; Program Advancing to Next Phase of Clinical Development in Multiple Myeloma and Non-Hodgkin’s Lymphoma CFT1946 Phase 1 Trial Continues t |
|
| January 14, 2025 |
Protein degraded. Disease targeted. Lives transformed. January 2025 Forward-looking Statements and Intellectual Property 2 FORWARD-LOOKING STATEMENTS The following presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” |
|
| January 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2025 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 9, 2024 |
December 2024 Protein degraded. Disease targeted. Lives transformed. Forward-looking Statements and Intellectual Property 2 Forward-looking Statements The following presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect, |
|
| December 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2024 (December 8, 2024) C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorpor |
|
| December 9, 2024 |
Exhibit 99.2 C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent Clinical Benefit Rate (CBR); Responses |
|
| December 9, 2024 |
Updated Data in Multiple Myeloma and First Data in Non-Hodgkin’s Lymphoma from the Ongoing Cemsidomide Phase 1/2 Trial American Hematology Annual Meeting (ASH) December 8, 2024 Forward-looking Statements and Intellectual Property 2 FORWARD-LOOKING STATEMENTS The following presentation contains forward-looking statements. |
|
| November 20, 2024 |
Exhibit 99.1 C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors Hoerter Brings Over Three Decades of Oncology Commercialization and Leadership Experience Appointment Underscores Continued Transformation of Board to Lead C4T into Next Phase of Pipeline Progress WATERTOWN, Mass., November 20, 2024 (GLOBE NEWSWIRE) - C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC) |
|
| November 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2024 (November 19, 2024) C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorp |
|
| November 15, 2024 |
Up to $200,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-282933 PROSPECTUS SUPPLEMENT (to Prospectus dated November 13, 2024) Up to $200,000,000 Common Stock We have entered into a sales agreement, or the Sales Agreement, with TD Securities (USA) LLC, which we refer to as TD Cowen or the Sales Agent, relating to shares of our common stock, par value $0.0001 per share, offered by this prospectus suppl |
|
| November 15, 2024 |
Up to 4,874,550 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-282934 PROSPECTUS Up to 4,874,550 Shares of Common Stock This prospectus relates to the resale, from time to time, by the selling stockholder named in this prospectus, or the Selling Stockholder, or any of their pledgees, donees, assignees and successors-in-interest, or collectively, the permitted transferees, of shares of our common stock that |
|
| November 14, 2024 |
SC 13G/A 1 p24-3207sc13ga.htm C4 THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* C4 Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 12529R107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Ch |
|
| November 14, 2024 |
CCCC / C4 Therapeutics, Inc. / ORBIMED ADVISORS LLC - SCHEDULE 13G Passive Investment SC 13G 1 ss4113334sc13g.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 C4 THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 12529R107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| November 14, 2024 |
SC 13G/A 1 p24-3172sc13ga.htm C4 THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* C4 Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 12529R107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Ch |
|
| November 14, 2024 |
CCCC / C4 Therapeutics, Inc. / COMMODORE CAPITAL LP Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* C4 Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 12529R107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropri |
|
| November 14, 2024 |
SC 13G/A 1 ea0221047-13ga1soleusc4ther.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* C4 THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 12529R107 (CUSIP Number) September 30, 2024 (Date of Event Which Re |
|
| November 13, 2024 |
Up to $200,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-282933 PROSPECTUS SUPPLEMENT (to Prospectus dated November 13, 2024) Up to $200,000,000 Common Stock We have entered into a sales agreement, or the Sales Agreement, with TD Securities (USA) LLC, which we refer to as TD Cowen or the Sales Agent, relating to shares of our common stock, par value $0.0001 per share, offered by this prospectus suppl |
|
| November 13, 2024 |
Up to 4,874,550 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-282934 PROSPECTUS Up to 4,874,550 Shares of Common Stock This prospectus relates to the resale, from time to time, by the selling stockholder named in this prospectus, or the Selling Stockholder, or any of their pledgees, donees, assignees and successors-in-interest, or collectively, the permitted transferees, of shares of our common stock that |
|
| November 8, 2024 |
490 Arsenal Way, Suite 120, Watertown, MA 02472 November 8, 2024 VIA EDGAR Office of Life Sciences Division of Corporation Finance U. |
|
| November 8, 2024 |
490 Arsenal Way, Suite 120, Watertown, MA 02472 November 8, 2024 VIA EDGAR Office of Life Sciences Division of Corporation Finance U. |
|
| October 31, 2024 |
Form of Subordinated Indenture between Registrant and one or more trustees to be named ACTIVE/122185841.2 Exhibit 4.5 C4 THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 202[●] Subordinated Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS Section 1.01 Definitions of Terms ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES Section 2.0 Designation and Terms of Securities Section 2.02 Form of Securities and Truste |
|
| October 31, 2024 |
Form of Senior Indenture between Registrant and one or more trustees to be named ACTIVE/122185840.2 Exhibit 4.3 C4 THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 202[●] Senior Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS Section 1.01 Definitions of Terms ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES Section 2.01 Designation and Terms of Securities Section 2.02 Form of Securities and Trustee’s C |
|
| October 31, 2024 |
As filed with the Securities and Exchange Commission on October 31, 2024 As filed with the Securities and Exchange Commission on October 31, 2024 Registration No. |
|
| October 31, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) C4 Therapeutics, Inc. |
|
| October 31, 2024 |
As filed with the Securities and Exchange Commission on October 31, 2024 As filed with the Securities and Exchange Commission on October 31, 2024 Registration No. |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39567 C4 Therapeutics, Inc. |
|
| October 31, 2024 |
‘Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) C4 Therapeutics, Inc. |
|
| October 31, 2024 |
, 2024 between the Registrant and TD Securities (USA) LLC Exhibit 1.2 ACTIVE/132189260.2 ACTIVE/132189260.4 C4 THERAPEUTICS, INC. SHARES OF COMMON STOCK SALES AGREEMENT October 31, 2024 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: C4 Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: 1. Issuance and Sale |
|
| October 31, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2024 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 31, 2024 |
Exhibit 99.1 C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights Cemsidomide Phase 1/2 Trial in Multiple Myeloma and non-Hodgkin’s Lymphoma Continues to Progress: Data from Both Indications to be Presented at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, CA Initial Monotherapy CFT1946 Phase 1 Data Demonstrated Well-Tolerated Safe |
|
| October 16, 2024 |
Exhibit 99.1 C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D. Mahaney Brings More Than 25 Years of Pharmaceutical and Biotech Experience Overseeing Drug Discovery and Expansion of Leading Discovery and Clinical Portfolios Fisher Will Serve as Senior Scientific Advisor Until December 31, 2024 WATERTOWN, Mass., October 15, 2 |
|
| October 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2024 (October 11, 2024) C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorp |
|
| October 16, 2024 |
Consulting Agreement dated as of October 15, 2024, between C4 Therapeutics, Inc. and Stewart Fisher REDACTED REDACTED |
|
| October 15, 2024 |
Consulting Agreement dated as of October 15, 2024, between C4 Therapeutics, Inc. and Stewart Fisher REDACTED REDACTED |
|
| October 15, 2024 |
Exhibit 99.1 C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D. Mahaney Brings More Than 25 Years of Pharmaceutical and Biotech Experience Overseeing Drug Discovery and Expansion of Leading Discovery and Clinical Portfolios Fisher Will Serve as Senior Scientific Advisor Until December 31, 2024 WATERTOWN, Mass., October 15, 2 |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2024 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 11, 2024 |
Amendment No. 1 to C4 Therapeutics, Inc. 2020 Stock Option and Incentive Plan ACTIVE/104115174.6 C4 THERAPEUTICS, INC. AMENDMENT NO. 1 TO 2020 STOCK OPTION AND INCENTIVE PLAN This Amendment No. 1 (the “Amendment”) to the C4 Therapeutics, Inc. (“Company”) 2020 Stock Option and Incentive Plan (the “Plan”) amends the Plan as set forth below, effective as of October 7, 2024, which is the date this Amendment was approved by the Company’s Board of Directors (the “Board”). All cap |
|
| October 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2024 (October 7, 2024) C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorpora |
|
| September 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2024 (August 29, 2024) C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorpor |
|
| September 3, 2024 |
C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors Exhibit 99.1 C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors WATERTOWN, Mass., September 3, 2024 (GLOBE NEWSWIRE) - C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the continued evolution of its Board of Directors with the appointment |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39567 C4 Therapeutics, Inc. |
|
| August 1, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 1, 2024 |
EX-99.1 2 cccc-20240801xexx991.htm EX-99.1 Exhibit 99.1 C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights Preliminary Monotherapy Data from the Ongoing CFT1946 Phase 1 Trial in BRAF V600X Solid Tumors to be Presented at ESMO Congress 2024; Initiated Monotherapy Expansion Cohort in Melanoma and Combination Cohort with Cetuximab in Colorectal Cancer Cemsido |
|
| June 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2024 (June 20, 2024) C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) |
|
| June 10, 2024 |
Exhibit 99.1 C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors Cooper Brings Decades of Global Pharmaceutical and Biotechnology Leadership Experience Bruce Downey Remains a Member of the Board of Directors and Chair of the Organization, Leadership and Compensation Committee Transition Further Highlights Commitment to Strategically Transform the Board to Lead C4T into Next P |
|
| June 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2024 (June 7, 2024) C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) |
|
| May 8, 2024 |
Exhibit 99.1 C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights Successfully Delivered First Development Candidate to Biogen; $8 Million Payment Earned Established a Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Focused on Two Critical Oncogenic Proteins Progressed Phase 1 Dose Escalation Trials for Cemsidomide (CFT7455) an |
|
| May 8, 2024 |
ACTIVE/128326788.11 Confidential Execution Copy Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. RESEARCH COLLABORATION AND LICENSE AGREEMENT by and between C4 THERAPE |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39567 C4 Therapeutics, Inc. |
|
| May 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended DECEMBER 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39567 C4 Therapeutics |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a6(e)( |
|
| April 29, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a6(e) |
|
| March 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2024 (March 7, 2024) C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024 (March 1, 2024) C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) |
|
| March 4, 2024 |
Exhibit 99.1 C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins Collaboration Focused on Two Targeted Protein Degraders from C4T’s Internal Discovery Pipeline C4T to Receive a $16 Million Upfront Payment; Merck KGaA, Darmstadt, Germany, to Cover Discovery Research Costs Under the Collaboration C4T Eligible f |
|
| February 22, 2024 |
, dated December 11, 2023, by and between C4 Therapeu EXECUTION VERSION Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. |
|
| February 22, 2024 |
Exhibit 99.1 C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights CFT1946 Preclinical Data Accepted for a Poster Presentation at the AACR Annual Meeting 2024 Phase 1 Dose Escalation Trials for CFT7455 and CFT1946 Continue to Progress; Data from Both Trials Expected in 2H 2024 Well Capitalized with Cash Runway Expected into 2027 WATERTOWN, Mass. |
|
| February 22, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) C4 Therapeutics, Inc. |
|
| February 22, 2024 |
Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Incorporation C4T Securities Corporation Massachusetts |
|
| February 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended DECEMBER 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-395 |
|
| February 22, 2024 |
Executive Compensation Clawback Policy ACTIVE/119833921.13 C4 THERAPEUTICS, INC. EXECUTIVE COMPENSATION RECOVERY POLICY 1. Overview This Executive Compensation Recovery Policy (the “Policy”) sets forth the circumstances and procedures under which the C4 Therapeutics, Inc. (together with any of its parent companies or subsidiaries, the “Company”) shall recover Erroneously Awarded Compensation from current and former Executive Officers o |
|
| February 22, 2024 |
Form of Non-Qualified Stock Option Agreement Inducement Award ACTIVE/104115192.2 C4 THERAPEUTICS, INC. NON-QUALIFIED STOCK OPTION AGREEMENT (INDUCEMENT GRANT) Name of Optionee: No. of Option Shares: Option Exercise Price per Share: $ [FMV on Grant Date] Grant Date: Expiration Date: C4 Therapeutics, Inc. (the “Company”) hereby grants to the Optionee named above an option (the “Stock Option”) to purchase on or prior to the Expiration Date specified above all o |
|
| February 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under The Securities Act of 1933 C4 Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) Delaware 47-5617627 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 490 Arsenal Way, Suite 120 Watertown, MA 02472 (Address of princip |
|
| February 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 14, 2024 |
SC 13G/A 1 p24-0772sc13ga.htm C4 THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* C4 Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 12529R107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Che |
|
| February 14, 2024 |
CCCC / C4 Therapeutics, Inc. / RTW INVESTMENTS, LP - C4 THERAPEUTICS, INC. Passive Investment SC 13G/A 1 p24-0391sc13ga.htm C4 THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* C4 Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 12529R107 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Che |
|
| February 5, 2024 |
CCCC / C4 Therapeutics, Inc. / Soleus Capital Master Fund, L.P. - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* C4 THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 12529R107 (CUSIP Number) January 26, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| February 2, 2024 |
SC 13G/A 1 ea192410-13ga1soleusc4thera.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* C4 THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 12529R107 (CUSIP Number) December 31, 2023 (Date of Event Which Req |
|
| January 12, 2024 |
CCCC / C4 Therapeutics, Inc. / Betta Investment (Hong Kong) Ltd. - SC 13G Passive Investment SC 13G 1 d636659dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* C4 Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 12529R107 (CUSIP Number) January 4, 2024 (Date of Event Which Requires Filing of this Statement) Check the ap |
|
| January 12, 2024 |
EX-99.1 2 d636659dex991.htm EX-99.1 EXHIBIT 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The unders |
|
| January 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2024 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 11, 2024 |
c4tjanuarycorporateprese January 2024 Protein degraded. Disease targeted. Lives transformed. Forward-looking Statements and Intellectual Property 2 Forward-looking Statements The following presentation contains forward-looking statements. All statements other than statements of historical fact are forward- looking statements, which are often indicated by terms such as “anticipate,” “believe,” “cou |
|
| January 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2024 (January 8, 2024) C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporat |
|
| January 9, 2024 |
C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines Multiple 2024 Clinical Updates Expected, Including Data from the Ongoing CFT7455 and CFT1946 Phase 1 Dose Escalation Trials Prioritization of CFT7455, CFT1946, Discovery Collaborations and Focused Discovery Research Efforts Results in Workforce Reduction of Approximately 30% Unaudited Cash, Cash Equivalents and Marketable Securities Totaling Approximately $330 million as of January 5, 2024, Combined with Cost Savings from Restructured Operations, Results in Cash Runway into 2027 Company to Present at the 42nd Annual J. |
|
| January 4, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* C4 Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 12529R107 (CUSIP Number) January 3, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| January 4, 2024 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned ackn |
|
| December 26, 2023 |
CCCC / C4 Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* C4 THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 12529R107 (CUSIP Number) December 14, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| December 22, 2023 |
CCCC / C4 Therapeutics, Inc. / COMMODORE CAPITAL LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| December 22, 2023 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. |
|
| December 12, 2023 |
Exhibit 99.1 C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs) Initial Focus on One Oncology Target, Exclusive to Collaboration; Merck has Option for Three Additional Targets WATERTOWN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) – C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedic |
|
| December 12, 2023 |
Exhibit 99.1 C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma Data Support 14 Days On/14 Days Off as Optimal Dosing Schedule; CFT7455 is Well Tolerated with Promising Signs of Anti-Myeloma Activity Completed Monotherapy Dose Escalation Demonstrates Anti-Myeloma Activity and Immunomodulatory Effects to Support CFT7455 in Combination with Nov |
|
| December 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2023 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2023 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 12, 2023 |
cft7455datapresentation CFT7455, IKZF1/3 Degrader, for the Potential Treatment of Relapsed Refractory Multiple Myeloma (R/R MM) December 12, 2023 Phase 1 Dose Escalation Data Forward-looking Statements and Intellectual Property 2 Forward-looking Statements The following presentation contains forward-looking statements. |
|
| November 20, 2023 |
Exhibit 99.1 C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment Owen Hughes, Accomplished Life Sciences Executive with Deep Experience Across Investing, Operations and Governance, Appointed as Independent Member of the Board of Directors WATERTOWN, Mass., November 20, 2023 (GLOBE NEWSWIRE) – C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical com |
|
| November 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2023 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 13, 2023 |
EX-99.1 2 p23-2700exhibit99.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agr |
|
| November 13, 2023 |
CCCC / C4 Therapeutics Inc / Lynx1 Capital Management LP - C4 THERAPEUTICS, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* C4 Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 12529R107 (CUSIP Number) November 1, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| November 1, 2023 |
Exhibit 99.1 C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights Portfolio Decision to Prioritize Ongoing Phase 1/2 Trials of CFT7455, an IKZF1/3 Degrader, and CFT1946, a BRAF V600 Degrader CFT8634, a BRD9 Degrader, Will Not Advance in Synovial Sarcoma and SMARCB-1 Null Tumors Due to Insufficient Single Agent Efficacy, Despite High Levels of BRD9 Degradation |
|
| November 1, 2023 |
ACTIVE/119833921.13 C4 THERAPEUTICS, INC. EXECUTIVE COMPENSATION RECOVERY POLICY 1. Overview This Executive Compensation Recovery Policy (the “Policy”) sets forth the circumstances and procedures under which the C4 Therapeutics, Inc. (together with any of its parent companies or subsidiaries, the “Company”) shall recover Erroneously Awarded Compensation from current and former Executive Officers o |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39567 C4 Therapeutics, Inc. |
|
| September 5, 2023 |
C4 Therapeutics Announces Chief Financial Officer Succession Exhibit 99.1 C4 Therapeutics Announces Chief Financial Officer Succession WATERTOWN, Mass., September 5, 2023 (GLOBE NEWSWIRE) - C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced the appointmen |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2023 (August 30, 2023) C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorpor |
|
| August 8, 2023 |
Exhibit 99.1 C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights Established Exclusive Licensing Agreement for CFT8919, an EGFR L858R BiDAC™ Degrader, with Betta Pharmaceuticals in Greater China for NSCLC; U.S. IND Cleared Ongoing Phase 1/2 Clinical Trials of CFT7455, an IKZF1/3 MonoDAC™ Degrader, and CFT8634, a BRD9 BiDAC Degrader, Continue to Progress; Ph |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39567 C4 Therapeutics, Inc. |
|
| July 25, 2023 |
CCCC / C4 Therapeutics Inc / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 C4 THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 12529R107 (CUSIP Number) JULY 19, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which |
|
| June 20, 2023 |
C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer WATERTOWN, Mass., June 20, 2023 (GLOBE NEWSWIRE) – C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced the appointment of Le |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2023 (June 15, 2023) C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) |
|
| June 12, 2023 |
CCCC / C4 Therapeutics Inc / ArrowMark Colorado Holdings LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| May 30, 2023 |
C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC C4 Therapeutics to Receive a $10 Million Upfront Payment, a $25 Million Equity Investment and is Eligible to Receive up to $357 Million for Development and Commercial Milestones Plus Royalties on Net Sales in Greater China Betta Pharmaceuticals to Develop and Commercialize CFT8919 in Greater China and Eligible to Receive Royalties on Net Sales Outside of Greater China The Exclusive Licensing Agreement with Betta Pharmaceuticals Accelerates Development of CFT8919 in Key International Markets WATERTOWN, Mass. |
|
| May 30, 2023 |
Execution Version STOCK PURCHASE AGREEMENT between C4 Therapeutics, Inc., Betta Investment (Hong Kong) Limited and Betta Pharmaceuticals Co., Ltd. Dated as of May 29, 2023 ACTIVE/120028238.25 STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (this “Agreement”) is made as of May 29, 2023, by and among C4 Therapeutics, Inc., a Delaware corporation (the “Company”), Betta Investment (Hong Kong) L |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2023 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 30, 2023 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [*], HAS BEEN OMITTED BECAUSE C4 THERAPEUTICS, INC. |
|
| May 4, 2023 |
Exhibit 99.1 C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights Preclinical Data Presented at AACR Demonstrated CFT1946 is a Potent and Mutant-Selective BRAF V600 BiDAC™ Degrader; Phase 1/2 Clinical Trial Enrolling Patients Phase 1 Dose Escalation Data from the Ongoing Phase 1/2 Clinical Trials of CFT7455, an IKZF1/3 MonoDAC™ Degrader, and CFT8634, a BRD9 B |
|
| May 4, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39567 C4 Therapeutics, Inc. |
|
| April 28, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitte |
|
| April 28, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39567 C |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a6(e)( |
|
| April 18, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitte |
|
| April 14, 2023 |
CCCC / C4 Therapeutics Inc / Soleus Capital Master Fund, L.P. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* C4 THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 12529R107 (CUSIP Number) April 13, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| April 14, 2023 |
EX-99.A EXHIBIT A JOINT FILING AGREEMENT Soleus Capital Master Fund, L.P., a Cayman Islands exempted limited partnership, Soleus Capital, LLC, a Delaware limited liability company, Soleus Capital Group, LLC, a Delaware limited liability company, and Guy Levy, an individual, hereby agree to file jointly the statement on Schedule 13G to which this Joint Filing Agreement is attached, and any amendmen |
|
| February 23, 2023 |
As filed with the Securities and Exchange Commission on February 23, 2023 As filed with the Securities and Exchange Commission on February 23, 2023 Registration No. |
|
| February 23, 2023 |
2020 Stock Option and Incentive Plan and forms of award agreements thereunder C4 THERAPEUTICS, INC. 2020 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the C4 Therapeutics, Inc. 2020 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of C4 Therapeutics, Inc. (the “Company”) and its Affiliates upon whose ju |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-395 |
|
| February 23, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) C4 Therapeutics, Inc. |
|
| February 23, 2023 |
As filed with the Securities and Exchange Commission on February 23, 2023 As filed with the Securities and Exchange Commission on February 23, 2023 Registration No. |
|
| February 23, 2023 |
Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Incorporation C4T Securities Corporation Massachusetts |
|
| February 23, 2023 |
Exhibit 99.1 C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights Phase 1 Dose Escalation Data from the Ongoing Phase 1/2 Clinical Trials of CFT7455, an IKZF1/3 MonoDAC™ Degrader, and CFT8634, a BRD9 BiDAC™ Degrader, Expected in 2H 2023 Phase 1/2 Clinical Trial of CFT1946, a BRAF V600 BiDAC Degrader, Enrolling Patients; New CFT1946 Preclinical |
|
| February 23, 2023 |
Exhibit 99.1 C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights Phase 1 Dose Escalation Data from the Ongoing Phase 1/2 Clinical Trials of CFT7455, an IKZF1/3 MonoDAC™ Degrader, and CFT8634, a BRD9 BiDAC™ Degrader, Expected in 2H 2023 Phase 1/2 Clinical Trial of CFT1946, a BRAF V600 BiDAC Degrader, Enrolling Patients; New CFT1946 Preclinical |
|
| February 23, 2023 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) C4 Therapeutics, Inc. |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under The Securities Act of 1933 C4 Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) Delaware 47-5617627 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 490 Arsenal Way, Suite 120 Watertown, MA 02472 (Address of princip |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| February 14, 2023 |
CCCC / Cache Capital Corp. / RTW INVESTMENTS, LP - C4 THERAPEUTICS, INC. Passive Investment SC 13G/A 1 p23-0581sc13ga.htm C4 THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* C4 Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 12529R107 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this statement) Che |
|
| February 14, 2023 |
CCCC / Cache Capital Corp. / ArrowMark Colorado Holdings LLC Passive Investment SC 13G 1 arrowmark-cccc123122a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* C4 Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 12529R107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check t |
|
| February 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2023 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 9, 2023 |
Investor presentation of the Company dated January 2023 (furnished herewith) |
|
| January 9, 2023 |
C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines Phase 1/2 Trial of CFT7455, an IKZF1/3 MonoDAC™ Degrader, Continues to Progress with Phase 1 Dose Escalation Data Expected in 2H 2023; Enrollment Open for Arm Evaluating CFT7455 in Combination with Dexamethasone Phase 1/2 Trial of CFT8634, a BRD9 BiDAC™ Degrader, Continues to Progress with Phase 1 Dose Escalation Data Expected in 2H 2023; Clinical Pharmacokinetic and Pharmacodynamic Data is Supportive of Proof of Mechanism Phase 1/2 Trial of CFT1946, a BRAF-V600 BiDAC Degrader, Initiated in Solid Tumors Cash, Cash Equivalents and Marketable Securities of $366. |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39567 C4 Therapeutics, Inc. |
|
| November 3, 2022 |
C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights Exhibit 99.1 C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights The Phase 1/2 Clinical Trials of CFT7455, an IKZF1/3 MonoDAC™ Degrader, and CFT8634, a BRD9 BiDAC™ Degrader, Continue to Enroll Patients and Advance Through Dose Escalation IND Clearance Achieved for CFT1946, a BRAF-V600 BiDAC Degrader; On Track to Initiate the Phase 1/2 Clinical Trial by Year- |
|
| September 22, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2022 (June 22, 2022) C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporatio |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 4, 2022 |
C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights Exhibit 99.1 C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights ? CFT7455, a Novel IKZF1/3 Degrader, Advancing Through Dose Escalation Portion of Phase 1/2 Clinical Trial ? ? Phase 1/2 Clinical Trial for CFT8634, a BRD9 Degrader, Enrolling Patients and Progressing Through Phase 1 Dose Escalation ? ? Investigational New Drug (IND) Application for CFT1946, a |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39567 C4 Therapeutics, Inc. |
|
| August 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2022 (July 29, 2022) C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation |
|
| August 2, 2022 |
Exhibit 99.1 C4 Therapeutics Appoints Experienced Clinical Development Leaders Laura Bessen, M.D. and Donna Grogan, M.D. to Board of Directors ? Dr. Laura Bessen Brings More Than Two Decades of Experience Across Medical Affairs and Clinical Development in Support of Successful Product Launches ? ? Dr. Donna Grogan Joins as Accomplished Drug Development and Regulatory Strategy Leader With More than |
|
| June 24, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2022 (June 22, 2022) C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) |
|
| June 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2022 (June 15, 2022) C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) |
|
| June 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a6(e)( |
|
| June 10, 2022 |
CCCC / Cache Capital Corp. / ArrowMark Colorado Holdings LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| May 16, 2022 |
Exhibit 99.1 C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC? Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors WATERTOWN, Mass., May 16, 2022 (GLOBE NEWSWIRE) ? C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation sci |
|
| May 16, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2022 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a6(e)( |
|
| May 5, 2022 |
C4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights Exhibit 99.1 C4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights ? Data from Ongoing CFT7455 Phase 1/2 Trial Presented at the American Association for Cancer Research (AACR) Annual Meeting; Enrollment Continues in Cohorts B1 and C ? ? Phase 1/2 Clinical Trial Initiated for CFT8634, a BRD9 Degrader, for Patients with Synovial Sarcoma and SMARCB1-null Solid Tu |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39567 C4 Therapeutics, Inc. |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a6(e)( |
|
| April 29, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitte |
|
| April 8, 2022 |
CFT7455 Phase 1/2 Cohort A Data Investor Call American Association for Cancer Research Annual Meeting 2022 Abstract CT186 April 8, 2022 Exhibit 99. |
|
| April 8, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2022 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 8, 2022 |
Exhibit 99.1 C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF1/3 Degrader ? Single Agent CFT7455 Induces Deep and Durable Degradation of IKZF1/3 and Meaningful Decreases in Serum Free Light Chain at Doses Lower than Expected Based on Pre-clinical Studies ? ? CFT7455 Exhibits Differentiated Pharmacokinetics (PK) and Potency Relati |
|
| March 16, 2022 |
Exhibit 99.1 C4 Therapeutics Appoints Utpal Koppikar to Board of Directors ? Utpal Koppikar, Veteran Life Sciences Industry Financial Executive, Appointed as Independent Member of the Board of Directors, Chair of Audit Committee and Member of Organization, Leadership and Compensation Committee ? ? Appointment Reflects C4T?s Continued Commitment to Corporate Governance to Support Company Growth ? W |
|
| March 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2022 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| February 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 24, 2022 |
Exhibit 99.1 C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights ? Data from Cohort A of the Ongoing Phase 1/2 Trial of CFT7455, a Novel IKZF1/3 Degrader, Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting ? ? Pre-clinical Data on CFT7455; CFT8634, a BRD9 Degrader; and CFT1946, a BRAF V600X Degrader, Accepted for Pres |
|
| February 24, 2022 |
Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Incorporation C4T Securities Corporation Massachusetts |
|
| February 24, 2022 |
As filed with the Securities and Exchange Commission on February 24, 2022 As filed with the Securities and Exchange Commission on February 24, 2022 Registration No. |
|
| February 24, 2022 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) C4 Therapeutics, Inc. |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39567 C4 Therapeutics |
|
| February 14, 2022 |
EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. |
|
| February 14, 2022 |
CCCC / Cache Capital Corp. / Cormorant Asset Management, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* C4 Therapeutics Holdings, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 12529R107 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| February 14, 2022 |
CCCC / Cache Capital Corp. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* C4 Thereapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 12529R 107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d |
|
| February 14, 2022 |
CCCC / Cache Capital Corp. / RTW INVESTMENTS, LP - C4 THERAPEUTICS, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* C4 Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 12529R107 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant t |
|
| January 21, 2022 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorpo |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 10, 2022 |
Exhibit 99.1 C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation Portfolio ? Initial Phase 1 Data for CFT7455, a Novel IKZF1/3 Degrader, Expected in 1H 2022? ? IND Clearance Achieved for CFT8634, a Degrader Targeting BRD9; On Track to Initiate Phase 1 Trial in Synovial Sarcoma and SMARCB1-null Solid Tumors in 1H 2022? ? CFT1946, a BRAF V600X Degrader, Advancing To |
|
| November 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 24, 2021 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 30, 2021 |
Exhibit 10.1 THIRD AMENDMENT TO LEASE This THIRD AMENDMENT TO LEASE (this ?Third Amendment?) is made and entered into as of November 24, 2021 (the ?Effective Date?), by and between COLUMBIA MASSACHUSETTS ARSENAL OFFICE PROPERTIES, LLC, a Delaware limited liability company (?Landlord?) and C4 THERAPEUTICS, INC., a Delaware corporation (?Tenant?), who both mutually acknowledge and concur, as follows |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 10, 2021 |
Form of Senior Indenture between Registrant and one or more trustees to be named Exhibit 4.4 C4 THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Senior Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee?s Certificate |
|
| November 10, 2021 |
Exhibit 99.1 C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results ? Phase 1/2 study of CFT7455, a Novel IKZF1/3 Degrader, Progressing with Data Expected in 2022; Trial-in-Progress Poster Accepted for Presentation at 63rd ASH Annual Meeting ? ? Investigational New Drug (IND) Application for CFT8634, a Degrader Targeting BRD9 for the Treatment of Synovial Sarco |
|
| November 10, 2021 |
Sales Agreement, dated as of November 10, 2021 between the Registrant and Cowen and Company, LLC Exhibit 1.2 Execution Version C4 THERAPEUTICS, INC. SHARES OF COMMON STOCK SALES AGREEMENT November 10, 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: C4 Therapeutics, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Shares. The Company agrees |
|
| November 10, 2021 |
As filed with the Securities and Exchange Commission on November 10, 2021 Table of Contents As filed with the Securities and Exchange Commission on November 10, 2021 Registration No. |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39567 C4 Therapeutics, Inc. |
|
| November 10, 2021 |
Form of Subordinated Indenture between Registrant and one or more trustees to be named Exhibit 4.5 C4 THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Subordinated Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee?s Certif |
|
| August 11, 2021 |
Exhibit 99.1 C4 Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results ? Dosed First Patient in Phase 1/2 Clinical Trial of CFT7455, a novel IKZF1/3 Degrader, in Hematologic Malignancies; Data Expected in 2022 ? ? Received Orphan Drug Designation for CFT7455 for the Treatment of Multiple Myeloma ? ? Initiated Investigational New Drug (IND)-Enabling Activities for |
|
| August 11, 2021 |
Exhibit 99.2 C4 Therapeutics Announces FDA Orphan Drug Designation for CFT7455 for the Treatment of Multiple Myeloma WATERTOWN, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) ? C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that th |
|
| August 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39567 C4 Therapeutics, Inc. |
|
| August 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2021 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| June 21, 2021 |
EX-99.2 3 cccc-ex9929.htm EX-99.2 Exhibit 99.2 C4 Therapeutics Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares WATERTOWN, Mass., June 21, 2021 (GLOBE NEWSWIRE) – C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease |
|
| June 21, 2021 |
Exhibit 99.1 C4 Therapeutics Presents Pre-clinical Data on CFT7455, a Novel IKZF1/3 Degrader for the Treatment of Hematologic Malignancies, at the 16th Annual International Conference on Malignant Lymphoma ? CFT7455 Demonstrated High Binding Affinity to Cereblon and Target Selectivity in Non-Hodgkin?s Lymphoma Cell Models, Producing Rapid and Deep Degradation of IKZF1/3 Proteins ? ? CFT7455 Result |
|
| June 21, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-257067 Prospectus 4,250,000 shares Common stock We are offering 4,250,000 shares of our common stock in this offering. Our common stock is listed on The Nasdaq Global Market under the symbol ?CCCC.? The last reported sale price of our common stock on The Nasdaq Global Select Market on June 17, 2021 was $37.08 per share. We are |
|
| June 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2021 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* C4 THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE PER SHARE (Title of Class of Securities) 12529R107 (CUSIP Number) Cobro Ventures Opportunity Fund, L.P. Attention: Marc Cohen 1000 Wilson Blvd. #1800 Arlington, VA 22209 (202) 421-7 |
|
| June 15, 2021 |
Exhibit 1 Joint Filing Agreement In accordance with Rule 13d-1(k) under the Securities and Exchange Act of 1934, the persons or entities named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the shares of common stock of the Company and further agree that this joint filing agreement be included as an exhibit to this Schedule 13D. |
|
| June 14, 2021 |
Form of Underwriting Agreement Exhibit 1.1 [ ] C4 Therapeutics, Inc. UNDERWRITING AGREEMENT June [ ], 2021 J.P. MORGAN SECURITIES LLC JEFFERIES LLC EVERCORE GROUP L.L.C. As Representatives of the several Underwriters c/o J.P. MORGAN SECURITIES LLC 383 Madison Avenue New York, New York 10179 c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o EVERCORE GROUP L.L.C. 55 East 52nd Street New York, New York 10055 Ladies |
|
| June 14, 2021 |
Exhibit 99.1 C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT7455, An Orally Bioavailable MonoDAC for Hematologic Malignancies ? CFT7455 is Company?s First Program to Advance to Clinic ? WATERTOWN, Mass., June 14, 2021 (GLOBE NEWSWIRE) ? C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-mol |
|
| June 14, 2021 |
C4 Therapeutics Launches Proposed Public Offering Exhibit 99.2 C4 Therapeutics Launches Proposed Public Offering WATERTOWN, Mass., June 14, 2021 (GLOBE NEWSWIRE) ? C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that it has launched a proposed public offering of 4,250,000 |
|
| June 14, 2021 |
June 14, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jane Park Re: C4 Therapeutics, Inc. Registration Statement on Form S-1 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933, as amended, please be advised that we will take rea |
|
| June 14, 2021 |
June 14, 2021 Office of Life Sciences Division of Corporation Finance Securities and Exchange Commission 100 F Street, N. |
|
| June 14, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2021 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 14, 2021 |
As filed with the Securities and Exchange Commission on June 14, 2021. Table of Contents As filed with the Securities and Exchange Commission on June 14, 2021. |
|
| June 7, 2021 |
CFT8919 Pre-Clinical Data Investor Call June 7, 2021 Exhibit 99.2 Forward-looking Statements The following presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as ?anticipate,? ?believe,? ?could,? ?estimate,? ?expect,? ?goal,? ?intend,? ?look forward to,? ?may,? ?plan,? ?pot |
|
| June 7, 2021 |
Exhibit 99.1 C4 Therapeutics Presents Pre-clinical Data on CFT8919, A Selective Degrader of EGFR L858R, at Keystone Symposium on Targeted Protein Degradation ? CFT8919 Induces Tumor Regression in Pre-clinical Models Resistant to First- and Third-generation EGFR Inhibitors ? ? CFT8919 Demonstrates Intracranial Activity Pre-clinically, Indicating the Potential to be Effective Against CNS Metastases |
|
| June 7, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2021 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 26, 2021 |
Corporate Presentation May 2021 Exhibit 99.2 Forward-looking Statements The following presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as ?anticipate,? ?believe,? ?could,? ?estimate,? ?expect,? ?goal,? ?intend,? ?look forward to,? ?may,? ?plan,? ?potential,? ?predict,? ? |
|
| May 26, 2021 |
C4 Therapeutics to Advance CFT8919, A Selective Degrader of EGFR L858R, Into IND-enabling Studies EX-99.1 2 cccc-ex9917.htm EX-99.1 Exhibit 99.1 C4 Therapeutics to Advance CFT8919, A Selective Degrader of EGFR L858R, Into IND-enabling Studies – IND Submission for CFT8919 Anticipated mid-2022; Phase 1/2 Trial Initiation Expected by YE 2022 – – CFT8919 is Potent and Mutant-Selective BiDACTM Degrader of EGFR L858R for the Treatment of Non-Small Cell Lung Cancer – – CFT8919 Pre-clinical Data on EG |
|
| May 26, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2021 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2021 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 20, 2021 |
C4 Therapeutics Appoints Lauren White as Chief Financial Officer Exhibit 99.1 C4 Therapeutics Appoints Lauren White as Chief Financial Officer WATERTOWN, Mass., May 20, 2021 (GLOBE NEWSWIRE) ? C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced the appointment of Lauren White to the role of chief financial |
|
| May 19, 2021 |
Table of Contents Confidential Treatment Requested by C4 Therapeutics, Inc. Pursuant to 17 C.F.R. Section 200.83 As confidentially submitted to the Securities and Exchange Commission on May 19, 2021. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remain confidential. Registration No. 333? UNITED STATES SECURITIES |
|
| May 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39567 C4 Therapeutics, Inc. |
|
| May 13, 2021 |
Exhibit 99.1 C4 Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results ? Preclinical Data for CFT7455, a novel IKZF1/3 Degrader, in Non-Hodgkin's Lymphoma Xenograft Models Accepted for Presentation at the International Conference on Malignant Lymphoma (ICML) in June ? ? CFT7455 Phase 1/2 Clinical Trial in Multiple Myeloma and Non-Hodgkin?s Lymphomas On Track to In |
|
| April 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2021 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| April 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ?Preliminary Proxy Statement ?Confidential, for Use of the Commission Only (as permitted by Rule 14a6(e)(2) |
|
| April 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ?Preliminary Proxy Statement ?Confidential, for Use of the Commission Only (as permitted by Rule 14a6(e)(2) |
|
| March 11, 2021 |
Registration Statement on Form S-8, File No. 333-254145, filed by the Registrant on March 11, 2021 As filed with the Securities and Exchange Commission on March 11, 2021 Registration No. |
|
| March 11, 2021 |
Subsidiaries of the Registrant EX-21.1 5 cccc-ex211216.htm EX-21.1 Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Incorporation C4T Securities Corporation Massachusetts |
|
| March 11, 2021 |
Exhibit 99.1 C4 Therapeutics Reports Recent Business Highlights and Full Year 2020 Financial Results – Phase 1/2 Trial for Lead Candidate CFT7455, a MonoDAC™ Degrader Targeting IKZF1/3 for the Treatment of Hematologic Malignancies, On Track for 1H 2021 Initiation Following FDA Clearance of Investigational New Drug (IND) – – Abstract Highlighting the Discovery and Preclinical Development of CFT7455 |
|
| March 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39567 C4 Therapeutics |
|
| March 11, 2021 |
Exhibit 10.13 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. First Amendment To Amended and Restated license Agreement This First Amendment (the ?First Amendment?), effective as of November 12, 2020 (?Amendment Effective Date?) is an amendment to that certain Amended an |
|
| March 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2021 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| March 11, 2021 |
Exhibit 10.11 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. AMENDMENT NO. 1 TO COLLABORATIVE RESEARCH AND LICENSE AGREEMENT THIS AMENDMENT NO. 1 TO COLLABORATIVE RESEARCH AND LICENSE AGREEMENT ("Amendment") is made as of February 25, 2020, by and among C4 Therapeutics, |
|
| March 11, 2021 |
Exhibit 4.4 DESCRIPTION OF CAPITAL STOCK The summary of the general terms and provision of the registered securities of C4 Therapeutics, Inc. (?C4T,? ?we,? or ?our?) set forth below does not purport to be complete and is subject to and qualified in its entirety by reference to our Fifth Amended and Restated Certificate of Incorporation (our ?certificate of incorporation?) and our Second Amended an |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* C4 Therapeutics Holdings, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 12529R107 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* C4 Thereapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 12529R 107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| January 12, 2021 |
Exhibit 99.2 Cash Guidance Unaudited cash, cash equivalents and short-term investments as of December 31, 2020, were approximately $370 million. C4 Therapeutics, Inc. expects its cash, cash equivalents and short-term investments, including payments anticipated to be received under existing collaboration agreements, will be sufficient to fund its operating plan to the end of 2023. ACTIVE/106555018. |
|
| January 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2021 C4 THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39567 47-5617627 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| January 12, 2021 |
Corporate Presentation January 2021 Exhibit 99.1 Forward-looking Statements The following presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict |
|
| January 6, 2021 |
Exhibit 99.1 C4 Therapeutics Announces Key 2021 Milestones to Support Progress Toward Goal of Four Clinical-Stage Programs by Year-End 2022 – Investigational New Drug (IND) Application for Lead Candidate CFT7455, a MonoDAC™ targeting IKZF1/3 for the Treatment of Hematologic Malignancies, Under FDA Review; Initiation of Phase 1/2 Trial Expected in 1H 2021 – – IND Application Submission for CFT8634, |
